CEO, Petter Hartman, Morten Sommer, Ulf G. Andersson and Søren Bregenholt At the Medicon Valley Alliance´s Ordinary General Meeting 10th of April, Ulf G Andersson, CEO of Medeon Science Park & Incubator, Malmö was elected new vice-chairman of Medicon Valley Alliance. He
Below you will find the latest news from MVA. You can also sign up to our newsletter MVA Update.
MVA Update is an electronic newsletter providing you with news about MVA and an overview of our events and other relevant events in Medicon Valley. You can also check out our calendar for more information about life science events in the region.
If you have any questions regarding our news section or media inquiries then please contact David Munis Zepernick, Head of Press on +45 2498 1668.
“Life science växer över sundet” is the title of the recently published in-depth article in Swedish “Naturvetaren” about the many benefits of Medicon Valley collaboration. If you are familiar with the Swedish language, we will encourage you to read it.
Medicon Valley Alliance has assisted the editors of Nature, the acknowledged international journal of science, with their recently published special edition “Spotlight on Sweden and Medicon Valley“. Among the articles, we specially recommend “How a bridge brought science closer together” featuring
Which biotech venture capital firms in Europe have been most active in the past year and are likely to protagonize some of the biggest deals in European biotech in 2018? Where are they located? How do we open their eyes
The Medicon Valley Yearbook 2018 has just been published. The Medicon Valley Alliance Chairman of the Board of Directors, Søren Bregenholt, Corporate Vice President, Global Research Strategy and Operations, Novo Nordisk, has used the editorial to strongly recommend that Danish
The four scientists are Bart De Strooper from Belgium, Michel Goedert from Luxembourg, Christian Haass from Germany and John Hardy from the UK. They are recognised for their highly specialised studies of Alzheimer’s disease and other dementia disorders and are
According to the Danish CEO of Malmø-based, Ascelia Pharma, Magnus Corfitzen, the company, which has developed a contrast agent, Mangoral, that can replace the controversial agent Omniscan, are considering several options for funding the millions of dollars need for future studies. A
Thanks to the following six companies, Novo Nordisk, FMC, Ascendis Pharma, DTU, 3Shape and CP Kelco, our friends at Copenhagen Capacity have been able to launch their very first Life Science Talent Campaign, enabling them to attract international life science
By the end of last week, agreements were signed that will allow construction of the ESS Campus to begin this fall. The campus buildings include 18 500 square metres of offices, laboratories and workshops. The ESS Campus will consist of